Biomedical Research · us
Reducing the source of toxicity in the liver: siRNA therapy protects the brain in mice with a rare disease
Glutaric aciduria type 1 can cause irreversible neurological damage in early childhood. Researchers used RNA interference to suppress lysine metabolism in the liver, improving survival and brain pathology in mice and identifying blood markers for monitoring. Whether the approach can protect patients still requires validation in human trials.
For patients with glutaric aciduria type 1 (GA1), metabolic imbalance can lead to lifelong movement disorders. A new study places the starting point for brain-protective treatment in the liver: researchers used small interfering RNA (siRNA) to reduce the production of toxic metabolites, improving survival and brain pathology in mouse models of the disease and suggesting a new therapeutic direction for this rare genetic disorder.
The study was led by a Duke University team in collaboration with the University of Colorado Anschutz Medical Campus and Alnylam Pharmaceuticals, and was published on November 18 in Science Translational Medicine. Patients with GA1 lack glutaryl-CoA dehydrogenase (GCDH) and cannot complete lysine breakdown normally, causing harmful organic acids to accumulate and damage brain regions involved in movement control. Current care relies on restricting lysine intake and managing acute episodes, but still cannot fully prevent neurological complications.
The team chose to inhibit AASS, an enzyme upstream in the metabolic pathway, to reduce the source of downstream toxic products. The study used siRNA conjugated to N-acetylgalactosamine (GalNAc) to target liver cells and reduce expression of the mouse Aass gene. This strategy builds on the team's 2023 research: metabolites that cause brain injury can be produced in the liver and then enter the brain through the circulation, so modifying liver metabolism may also provide neuroprotection.
Duke University's account and a Medical Xpress report provided by the university stated that, in the reported experiments, all treated adult mice in the disease model survived. Survival among newborn mice was also better than in controls, with improvement still observed under a high-protein diet. The paper's abstract confirmed that the therapy improved brain pathology in newborn Gcdh-knockout mice and reduced toxic metabolites in the brain and other organs. These results provide evidence of protection in animals, but cannot be directly translated into treatment benefits for patients.
Another finding concerns how to determine whether treatment is working. The study identified blood markers, including glutaric acid, 3-hydroxyglutaric acid and glutarylcarnitine, that could predict neurological outcomes in the experimental animals. If subsequently validated in humans, these markers could help monitor treatment efficacy; they cannot currently be regarded as established surrogate markers of efficacy in humans.
Changes in blood and urine, however, did not occur in parallel. Peptide and Protein News specifically noted that although metabolite concentrations throughout the body declined, urinary excretion remained elevated. The paper's abstract also documented this finding, considering it consistent with continued renal clearance of metabolites and preserved excretory capacity. This means that, when evaluating therapies of this kind in the future, urine measurements alone may be insufficient to reflect whether the body's toxic burden has decreased.
The research team hopes to advance to human trials, but the current findings remain preclinical. The publicly available abstract and news materials did not fully report sample sizes for each group, doses or follow-up periods, leaving insufficient information to determine how long the protective effect might last. For young children who are still developing, the safety of long-term suppression of this metabolic pathway, the appropriate timing of intervention, and whether blood markers can reflect neuroprotection are all questions that must be answered once clinical studies begin.